Oncotarget

Research Papers:

Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases

Valerio Leoni, Valentina Gatta, Arianna Palladini, Giordano Nicoletti, Dario Ranieri, Massimiliano Dall’Ora, Valentina Grosso, Martina Rossi, Francesco Alviano, Laura Bonsi, Patrizia Nanni, Pier-Luigi Lollini and Gabriella Campadelli-Fiume _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:34774-34787. https://doi.org/10.18632/oncotarget.5793

Metrics: PDF 3103 views  |   HTML 3496 views  |   ?  


Abstract

Valerio Leoni1,*, Valentina Gatta1,*, Arianna Palladini1, Giordano Nicoletti1, Dario Ranieri1, Massimiliano Dall’Ora1, Valentina Grosso1, Martina Rossi1, Francesco Alviano1, Laura Bonsi1, Patrizia Nanni1, Pier-Luigi Lollini1 and Gabriella Campadelli-Fiume1

1 Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy

* These authors have contributed equally to this work

Correspondence to:

Gabriella Campadelli-Fiume, email:

Pier-Luigi Lollini, email:

Keywords: oncolytic herpes simplex virus, viral retargeting, mesenchymal stem cells, systemic delivery, metastases

Received: July 02, 2015 Accepted: September 04, 2015 Published: September 27, 2015

Abstract

Fully retargeted oncolytic herpes simplex viruses (o-HSVs) gain cancer-specificity from redirection of tropism to cancer-specific receptors, and are non-attenuated. To overcome the hurdles of systemic delivery, and enable oncolytic viruses (o-viruses) to reach metastatic sites, carrier cells are being exploited. Mesenchymal stromal cells (MSCs) were never tested as carriers of retargeted o-viruses, given their scarse-null expression of the cancer-specific receptors. We report that MSCs from different sources can be forcedly infected with a HER2-retargeted oncolytic HSV. Progeny virus spread from MSCs to cancer cells in vitro and in vivo. We evaluated the organ distribution and therapeutic efficacy in two murine models of metastatic cancers, following a single i.v. injection of infected MSCs. As expected, the highest concentration of carrier-cells and of viral genomes was in the lungs. Viral genomes persisted throughout the body for at least two days. The growth of ovarian cancer lung metastases in nude mice was strongly inhibited, and the majority of treated mice appeared metastasis-free. The treatment significantly inhibited also breast cancer metastases to the brain in NSG mice, and reduced by more than one-half the metastatic burden in the brain.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5793